Receive a free case review.
Novartis manufactures and markets Elidel to treat eczema, an allergic
reaction that causes skin inflammation. The FDA approved Elidel in December 2001. Unfortunately, Elidel is linked to severe and fatal side effects, including skin cancer and lymphoma.
Elidel Linked to Cancerous Side Effects
On March 10, 2005, the FDA issued a Public Health Advisory announcing that animal studies link Elidel use to serious side effects, including skin cancer and lymphoma. The animal studies have shown that three different animal species developed cancer after exposure to Elidel, including mice, rats, and monkeys. The animal studies also concluded that the cancer side effect risk increased with higher doses and longer Elidel use.
The FDA further announced that a few patients have reported developing
|
Related Topics: |
Elidel Side Effects: Skin Cancer
Skin cancer is a serious side effect of Elidel. Skin Cancer is a severe and progressively worsening growth on the skin. Typically, skin cancer develops on the skin’s outermost layer, so the tumor is clearly visible. Therefore, skin cancer is usually detected in the early stages and non-fatal. Skin cancer side effects include:
Elidel Side Effects: Lymphoma
Lymphoma is a cancer that originates in the lymphocytes, a type of white blood cell. Lymphoma cancer is medically classified as a hematological malignancy, meaning it arises from the blood. Lymphoma’s most common symptom is enlarged, swelling of the lymph nodes in the neck, underarm, or groin. Other Lymphoma cancer side effects may include:
FDA Elidel Side Effects Warning
In January 2006, the FDA ordered Novartis to add a black box warning to Elidel’s label notifying healthcare providers and patients about the increased risk of cancerous side effects. The black box warning provides:
Injured by Elidel Cancerous Side Effects?
If you or a loved one developed skin cancer, lymphoma or other serious side effects after prolonged Elidel use, you may wish to consult with our attorneys about your legal rights.
Pimecrolimus